GSK

News

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed from sale.

News

Alector has abandoned latozinemab as a treatment for frontotemporal dementia, four years after GSK licensed the antibody in a $700m upfront deal.

News

GSK and Spero's cabapenem tebipenem is the first oral antibiotic in the class to show efficacy in complicated urinary tract infections.

News

ViiV's injectable HIV PrEP Apretude will soon be an alternative for people in England and Wales who cannot use daily oral options.

R&D

Exploring the growing threat of UTIs, the need for new antibiotics, and GSK’s role in advancing targeted treatments.

News

This week has kicked off with the news that Emma Walmsley is standing down as chief executive of GSK after eight years, to be replaced by Luke Miels.